Compare Ginkgo Bioworks Holdings Inc (DNA) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Weibo Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Weibo Corp trades at $6.54 (market cap $1.56B). The key difference: Weibo Corp is far larger — about 2× Ginkgo Bioworks Holdings Inc's market cap, and Weibo Corp pays a 9.47% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Weibo Corp for 102 Days on average.
| DNA | WB | |
|---|---|---|
Market Cap | $763.64M | $1.56B |
Volume | 3,204,177 | 812,503 |
Sector | Health | Media |
52-Week High | $15.83 | $11.61 |
52-Week Low | $5.48 | $6.33 |
Typical Hold Time | 7 Days | 102 Days |
Enterprise Value | $865.59M | $786.69M |
Dividend Yield | — | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.
The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.
Weibo (WB) trades at $6.44, down 0.62% with a bearish technical outlook. The stock shows attractive valuation metrics with P/E of 5.32 and P/B of 0.4, while maintaining strong profitability with 73.36% gross margins. Recent Q2 2026 earnings beat expectations with $0.38 EPS, though Q4 2025 and Q1 2026 missed. Cash flow trends show volatility, with 2024 net cash flow negative $694 million but improving to positive $408 million in 2025. Analyst sentiment is mixed with 40.91% buy ratings amid concerns about user growth stagnation.
WB presents as a deep-value opportunity with compelling valuation multiples but faces headwinds from declining user metrics and advertising revenue challenges. The risk-reward profile favors patient investors willing to tolerate near-term volatility for potential multiple expansion, though competitive pressures and regulatory uncertainties in China's social media landscape require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
